Microba Life Sciences Completes Screening for Autoimmune Disease Program; Shares Down 3%

MT Newswires Live06-28

Microba Life Sciences (ASX:MAP) completed screening activities for its autoimmune disease therapeutic discovery program in partnership with Ginkgo Bioworks, according to a Friday filing with the Australian Securities Exchange.

Under the program, six therapeutic leads with strong disease-relevant activity have been chosen for further preclinical development. Leads with strong immunomodulatory effects in a variety of disease-relevant cell types were found through the screening, the filing said.

The program's next phases include evaluating the therapeutic efficacy of the lead strains in disease-relevant animal models and manufacturing for clinical trials, the company said.

Shares fell 3% in midday trading.

Price (AUD): $0.16, Change: $-0.01, Percent Change: -3.03%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446548903?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-28 11:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446548903","market":"nz","top_or_hot":-1,"title":"Microba Life Sciences Completes Screening for Autoimmune Disease Program; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> Microba Life Sciences (ASX:MAP) completed screening activities for its autoimmune disease therapeutic discovery program in partnership with Ginkgo Bioworks, according to a Friday filing with the Australian Securities Exchange.</p><p>Under the program, six therapeutic leads with strong disease-relevant activity have been chosen for further preclinical development. Leads with strong immunomodulatory effects in a variety of disease-relevant cell types were found through the screening, the filing said.</p><p>The program's next phases include evaluating the therapeutic efficacy of the lead strains in disease-relevant animal models and manufacturing for clinical trials, the company said.</p><p>Shares fell 3% in midday trading.</p><p>Price (AUD): $0.16, Change: $-0.01, Percent Change: -3.03%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microba Life Sciences Completes Screening for Autoimmune Disease Program; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicroba Life Sciences Completes Screening for Autoimmune Disease Program; Shares Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-28 11:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Microba Life Sciences (ASX:MAP) completed screening activities for its autoimmune disease therapeutic discovery program in partnership with Ginkgo Bioworks, according to a Friday filing with the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MAP.AU","symbol_name":"MICROBA LIFE SCIENCES LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2446548903","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446548903","pubTimestamp":1719543712,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Microba Life Sciences  completed screening activities for its autoimmune disease therapeutic discovery program in partnership with Ginkgo Bioworks, according to a Friday filing with the Australian Securities Exchange.Under the program, six therapeutic leads with strong disease-relevant activity have been chosen for further preclinical development. Leads with strong immunomodulatory effects in a variety of disease-relevant cell types were found through the screening, the filing said.The program's next phases include evaluating the therapeutic efficacy of the lead strains in disease-relevant animal models and manufacturing for clinical trials, the company said.Shares fell 3% in midday trading.Price : $0.16, Change: $-0.01, Percent Change: -3.03%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MAP.AU":"MICROBA LIFE SCIENCES LTD","BK4125":"广播","AUD":"Audacy Inc.","BK7124":"保健护理服务"},"translate_title":"Microba Life Sciences完成自身免疫性疾病筛查计划；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"MAP.AU":0.9},"content_text":"Microba Life Sciences (ASX:MAP) completed screening activities for its autoimmune disease therapeutic discovery program in partnership with Ginkgo Bioworks, according to a Friday filing with the Australian Securities Exchange.Under the program, six therapeutic leads with strong disease-relevant activity have been chosen for further preclinical development. Leads with strong immunomodulatory effects in a variety of disease-relevant cell types were found through the screening, the filing said.The program's next phases include evaluating the therapeutic efficacy of the lead strains in disease-relevant animal models and manufacturing for clinical trials, the company said.Shares fell 3% in midday trading.Price (AUD): $0.16, Change: $-0.01, Percent Change: -3.03%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446548903"}